FOXO4-DRI
Senolytic Peptide — Proxofim
D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells. Studied for selective clearance of senescent cells (senolytic activity) while sparing healthy tissue.
Format
10mg / vial
Purity
>98.5%
Category
Longevity
Storage
2–8 °C
Research Price
€279
10mg / vial
RESEARCH USE ONLY
This compound is sold exclusively for in-vitro laboratory research. It is not intended for human consumption, therapeutic use, or self-administration. You must be 18+ and a qualified researcher to purchase.
Complete Your Research with the Pen Kit
Precise, painless, repeatable. The clinical-grade injection pen with 32G ultra-fine needles, bacteriostatic water, and your choice of peptide — ready to use out of the box.
€189
View details →Documented Research Parameters
Research Dose
1–5 mg
Frequency
3× per week
Duration
3 weeks (typical cycle)
Half-Life
Not fully established
Route(s)
Subcutaneous · Intraperitoneal (animal research)
Solubility
Water (may require gentle warming)
Reconstitution
1 ml bacteriostatic water per 10 mg vial
Key Research Findings
D-retro-inverso isomer design confers protease resistance, extending in vivo stability.
Disrupts FOXO4-p53 interaction specifically in senescent cells — mechanism confers selectivity over healthy tissue.
Published data (de Keizer et al., 2017) demonstrated restoration of exercise tolerance and hair regrowth in fast-aged mouse models.
Among the most selective senolytics characterised; navitoclax and dasatinib/quercetin are broader comparators.
Administration Reference
Subcutaneous injection in abdominal sites. Published animal research used intraperitoneal injection; subcutaneous is the closest human-applicable route studied. Three-week cycle protocols (3× per week) reflect the original de Keizer laboratory design.
Documented Combination Protocols
Senolytic + telomere biology — cellular clearance combined with telomerase activation research.
Post-senolytic immune support — thymic restoration after cellular clearance in aging models.
IMPORTANT RESEARCH DISCLAIMER
This compound is for in-vitro research and laboratory use only. It has not been evaluated or approved by any regulatory authority for human therapeutic use. It must not be used as a food, drug, or cosmetic. SYNTHEXA assumes no liability for misuse. Handle in accordance with Good Laboratory Practice.